PeptideAgentAsk PeptideAgent
Comparisons/Thymosin Alpha-1 vs LL-37
PEPTIDE COMPARISON

Thymosin Alpha-1 vs LL-37

An immune-modulating therapeutic candidate compared with an endogenous antimicrobial peptide.

QUICK ANSWER

Thymosin Alpha-1 vs LL-37: the main difference.

Thymosin alpha-1 has substantially more human research, though results remain indication-specific. LL-37's importance in innate immunity is not evidence that administering an LL-37 product improves immune function.

Decision fieldThymosin Alpha-1 LL-37
Human researchMultiple indication-specific trialsNo established marketed-product efficacy program
Primary biologyImmune modulationHost defense, inflammation, and antimicrobial activity
FDA statusNo U.S.-approved product identifiedNot approved; compounding safety concerns
Main uncertaintyConsistency across indications and study qualitySafety and therapeutic translation
Evidence confidenceModerate but indication-specificVery low for administered products

SOURCES

Thymosin Alpha-1 vs LL-37 sources.

Human trial / 2025Thymosin alpha-1 for sepsis: multicenter randomized phase 3 trialPubMed Review / 2025Thymosin alpha-1 in sepsis: systematic review and meta-analysisPubMed WADA / 20262026 Prohibited ListWorld Anti-Doping Agency Review / 2025LL-37 in immunity and diseasePubMed Preclinical / 1998Antimicrobial activity of human cathelicidin LL-37PubMed FDA / 2026Bulk substances that may present significant safety risksU.S. FDA

RELATED QUESTIONS

Questions related to Thymosin Alpha-1 vs LL-37.

What is Thymosin Alpha-1?What is LL-37?What is the evidence for Thymosin Alpha-1?What is the evidence for LL-37?

RELATED COMPARISONS

Thymosin Alpha-1 vs Thymosin Beta-4KPV vs LL-37